Abuse Liability of Controlled-Release Oxycodone Formulations

PHASE4CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Substance-Related Disorders
Interventions
DRUG

Apo-Oxycodone CR®

a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®

DRUG

OxyNEO®

a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®

DRUG

Placebo

a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products

Trial Locations (1)

M5S 2S1

Centre for Addiction and Mental Health, Toronto

All Listed Sponsors
collaborator

University of Toronto

OTHER

lead

Centre for Addiction and Mental Health

OTHER

NCT02101840 - Abuse Liability of Controlled-Release Oxycodone Formulations | Biotech Hunter | Biotech Hunter